Skip to main content
NCBI home page
The British Journal of General Practice logoLink to The British Journal of General Practice
. 2003 Mar;53(488):191–196.

A case-control study on the effect of hormone replacement therapy on ischaemic heart disease.

Julia Hippisley-Cox 1, Mike Pringle 1, Nicola Crown 1, Carol Coupland 1
PMCID: PMC1314543  PMID: 14694694

Abstract

BACKGROUND: Many clinicians believe that hormone replacement therapy (HRT) protects against coronary heart disease (CHD) in women. However, recent reports have cast some doubt on this because of lack of dose-response or duration-response effects. Since CHD is common in women--about half of all postmenopausal women will get it and about a third of these will die from it--the effect of HRT on CHD is of great public health importance. AIM: To determine the degree of cardioprotection conferred by HRT, including the effect of duration, time since last issue, the addition of progestogens, route of administration, and dose. DESIGN: Population-based case-control study. SETTING: Nine general practices recruited from the Trent Focus Collaborative Research Network. METHOD: A total of 417 female cases with CHD matched by age and practice to 2435 controls with a case-control ratio of 1:5.8 were studied. The main outcome measure was the odds ratio for CHD calculated by conditional logistic regression adjusted for diabetes, hypertension, body mass index, and smoking. RESULTS: No evidence was found, either from univariate analysis or multivariate analysis, that use of HRT was associated with reduced risk of CHD (odds ratio = 1.32; 95% confidence interval = 0.93 to 1.87). Indeed, the trend was in the opposite direction. There was no association for different types of HRT (opposed or unopposed) or routes of administration. Similarly, there was no association for current or past use and no effect for dose or duration. CONCLUSION: This study adds to growing evidence that HRT does not confer cardioprotection. Until there is robust evidence to the contrary, general physicians need to assess risks and benefits of HRT independently of any possible reduction in risk of CHD.

Full Text

The Full Text of this article is available as a PDF (78.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrett-Connor E. Hormone replacement therapy. BMJ. 1998 Aug 15;317(7156):457–461. doi: 10.1136/bmj.317.7156.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Campbell N. C., Thain J., Deans H. G., Ritchie L. D., Rawles J. M. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ. 1998 May 9;316(7142):1430–1434. doi: 10.1136/bmj.316.7142.1430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cannon P. J., Connell P. A., Stockley I. H., Garner S. T., Hampton J. R. Prevalence of angina as assessed by a survey of prescriptions for nitrates. Lancet. 1988 Apr 30;1(8592):979–981. doi: 10.1016/s0140-6736(88)91790-4. [DOI] [PubMed] [Google Scholar]
  4. Dupont W. D. Power calculations for matched case-control studies. Biometrics. 1988 Dec;44(4):1157–1168. [PubMed] [Google Scholar]
  5. Grady D., Hulley S. B., Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA. 1997 Aug 13;278(6):477–477. [PubMed] [Google Scholar]
  6. Grodstein F., Manson J. E., Colditz G. A., Willett W. C., Speizer F. E., Stampfer M. J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000 Dec 19;133(12):933–941. doi: 10.7326/0003-4819-133-12-200012190-00008. [DOI] [PubMed] [Google Scholar]
  7. Grodstein F., Stampfer M. J., Manson J. E., Colditz G. A., Willett W. C., Rosner B., Speizer F. E., Hennekens C. H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996 Aug 15;335(7):453–461. doi: 10.1056/NEJM199608153350701. [DOI] [PubMed] [Google Scholar]
  8. Hammersley Vicky, Hippisley-Cox Julia, Wilson Andrew, Pringle Mike. A comparison of research general practices and their patients with other practices--a cross-sectional survey in Trent. Br J Gen Pract. 2002 Jun;52(479):463–468. [PMC free article] [PubMed] [Google Scholar]
  9. Hemminki E., McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ. 1997 Jul 19;315(7101):149–153. doi: 10.1136/bmj.315.7101.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Herrington D. M., Reboussin D. M., Brosnihan K. B., Sharp P. C., Shumaker S. A., Snyder T. E., Furberg C. D., Kowalchuk G. J., Stuckey T. D., Rogers W. J. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000 Aug 24;343(8):522–529. doi: 10.1056/NEJM200008243430801. [DOI] [PubMed] [Google Scholar]
  11. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 Aug 19;280(7):605–613. doi: 10.1001/jama.280.7.605. [DOI] [PubMed] [Google Scholar]
  12. Khaw K. T. Hormone replacement therapy again. Risk-benefit relation differs between populations and individuals. BMJ. 1998 Jun 20;316(7148):1842–1844. doi: 10.1136/bmj.316.7148.1842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Michaëlsson K., Baron J. A., Farahmand B. Y., Johnell O., Magnusson C., Persson P. G., Persson I., Ljunghall S. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ. 1998 Jun 20;316(7148):1858–1863. doi: 10.1136/bmj.316.7148.1858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Posthuma W. F., Westendorp R. G., Vandenbroucke J. P. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 1994 May 14;308(6939):1268–1269. doi: 10.1136/bmj.308.6939.1268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rödström K., Bengtsson C., Lissner L., Björkelund C. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden. BMJ. 1999 Oct 2;319(7214):890–893. doi: 10.1136/bmj.319.7214.890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stampfer M. J., Colditz G. A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991 Jan;20(1):47–63. doi: 10.1016/0091-7435(91)90006-p. [DOI] [PubMed] [Google Scholar]
  17. Whitelaw F. G., Nevin S. L., Milne R. M., Taylor R. J., Taylor M. W., Watt A. H. Completeness and accuracy of morbidity and repeat prescribing records held on general practice computers in Scotland. Br J Gen Pract. 1996 Mar;46(404):181–186. [PMC free article] [PubMed] [Google Scholar]

Articles from The British Journal of General Practice are provided here courtesy of Royal College of General Practitioners

RESOURCES